QuestCap Announces Planned Name Change to Medi-Volve Along With Transition to Single Purpose Medical Company
TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (NEO:QSC; OTC:COPRF; FRA:34C1), is pleased to announce that it has initiated the process to change its corporate name to Medi-Volve in conjunction with its transition to a single purpose medical company, previously announced on October 13th, 2020. This name change is intended to emphasize the Company’s growth in the COVID-19 medical space and demonstrate the Company’s commitment to investing in innovative medical solutions that will combat the pandemic and help restore reality responsibly.
QuestCap has assembled a management team and advisory group of renowned medical experts. This team includes Dr. Lawrence Steinman, Professor of Neurology, Neurological Sciences and Paediatrics at Stanford University and former head of Immunology at Stanford. As well as Dr. Glenn Copeland, is one of North America’s most prominent foot and ankle specialists and founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.Their expertise guides the Company’s strategy for combatting the COVID-19 pandemic, including assessing the merit of novel technologies and clinical studies, as well as developing protocols and standards to help restores businesses. Further, this team is currently supporting the development of the Company’s long-term strategy in the medical space outside of pandemic-related initiatives.In accordance with company policy, QuestCap shareholders have been notified of the proposed name change and will vote to ratify the name change at the next Annual General Meeting (“AGM”), scheduled for December 3, 2020. The name change remains subject to shareholder and regulatory approval.“As QuestCap completed the transition to a single purpose medical company, our team saw an opportunity to rebrand to Medi-Volve to underscore to the market our singular focus on the world’s largest medical challenge – combatting COVID-19,” says Mr. Doug Sommerville, CEO of QuestCap. “We worked with our internal specialists to develop this new brand that we will champion as we make Medi-Volve an industry leader in the fight against COVID-19.”About QuestCap Inc.
QuestCap Inc. (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.For additional information, please contact:Doug Sommerville, CEO
+1 416-301-5418For investing inquiries please contact:
Evan.email@example.comFor US media enquires please contact:
+1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, the proposed name change. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.